- Home
- SMBK vs ATYR Comparison
SMBK vs ATYR Comparison
Compare SMBK & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- ATYR
- Stock Information
- Founded
- SMBK N/A
- ATYR 2005
- Country
- SMBK United States
- ATYR United States
- Employees
- SMBK N/A
- ATYR N/A
- Industry
- SMBK Major Banks
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMBK Finance
- ATYR Health Care
- Exchange
- SMBK Nasdaq
- ATYR Nasdaq
- Market Cap
- SMBK 553.9M
- ATYR 451.3M
- IPO Year
- SMBK N/A
- ATYR 2015
- Fundamental
- Price
- SMBK $35.48
- ATYR $5.30
- Analyst Decision
- SMBK Buy
- ATYR Strong Buy
- Analyst Count
- SMBK 5
- ATYR 6
- Target Price
- SMBK $34.40
- ATYR $20.20
- AVG Volume (30 Days)
- SMBK 65.9K
- ATYR 3.7M
- Earning Date
- SMBK 07-21-2025
- ATYR 08-12-2025
- Dividend Yield
- SMBK 0.90%
- ATYR N/A
- EPS Growth
- SMBK 44.84
- ATYR N/A
- EPS
- SMBK 2.26
- ATYR N/A
- Revenue
- SMBK $171,664,000.00
- ATYR N/A
- Revenue This Year
- SMBK $20.95
- ATYR $960.85
- Revenue Next Year
- SMBK $9.48
- ATYR $1,283.47
- P/E Ratio
- SMBK $15.65
- ATYR N/A
- Revenue Growth
- SMBK 16.34
- ATYR N/A
- 52 Week Low
- SMBK $24.33
- ATYR $1.58
- 52 Week High
- SMBK $37.72
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- SMBK 71.72
- ATYR 56.28
- Support Level
- SMBK $35.30
- ATYR $5.07
- Resistance Level
- SMBK $35.99
- ATYR $5.58
- Average True Range (ATR)
- SMBK 0.81
- ATYR 0.39
- MACD
- SMBK 0.23
- ATYR -0.04
- Stochastic Oscillator
- SMBK 87.30
- ATYR 64.20
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.